866-997-4948(US-Canada Toll Free)

Kaposi Sarcoma - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : May 2017

Category :

Pharmaceutical

No. of Pages : 76 Pages

Kaposi Sarcoma - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kaposi Sarcoma - Pipeline Review, H1 2017, provides an overview of the Kaposi Sarcoma (Infectious Disease) pipeline landscape.

Kaposi's sarcoma is a cancer that causes patches of abnormal tissue to grow under the skin, in the lining of the mouth, nose, and throat or in other organs. Symptoms include patches which are usually red or purple and are made of cancer cells and blood cells. Lesions that develop in the stomach and intestines can cause abdominal pain and diarrhea.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kaposi Sarcoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Kaposi Sarcoma (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kaposi Sarcoma (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Kaposi Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 1, 3, 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Kaposi Sarcoma (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Kaposi Sarcoma (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Kaposi Sarcoma (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Kaposi Sarcoma (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Kaposi Sarcoma (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Kaposi Sarcoma (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Kaposi Sarcoma (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Kaposi Sarcoma (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Kaposi Sarcoma - Overview
Kaposi Sarcoma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Kaposi Sarcoma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Kaposi Sarcoma - Companies Involved in Therapeutics Development
Aphios Corp
Cannabis Science Inc
CytRx Corp
LATITUDE Pharmaceuticals Inc
RedHill Biopharma Ltd
Tumorend LLC
VasGene Therapeutics Inc
Kaposi Sarcoma - Drug Profiles
ABC-294640 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aldoxorubicin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CM-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSTATI-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Dermos - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
doxorubicin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
interferon alfa-2a - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
interferon alfa-2b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
paclitaxel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit HAUSP for Lymphoma and Kaposi Sarcoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TLD-208 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vas-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Kaposi Sarcoma - Dormant Projects
Kaposi Sarcoma - Discontinued Products
Kaposi Sarcoma - Product Development Milestones
Featured News & Press Releases
Jun 06, 2016: CytRx Presents Updated Aldoxorubicin Clinical Trial Results at the 2016 American Society of Clinical Oncology Annual Meeting
May 26, 2016: $1.8 Million Fast-Track NIH SBIR Grant for Manocept Immunotherapeutics Evaluation in Kaposis Sarcoma Awarded to Navidea
May 03, 2016: Navidea and Macrophage Therapeutics to Provide Development Program Update
Apr 20, 2016: CytRx to Present Updated Aldoxorubicin Clinical Trial Data at the American Society of Clinical Oncology Annual Meeting in June 2016
Sep 03, 2015: Navidea Awarded $1.8M Fast Track NIH SBIR Grant for Evaluation of a Manocept Agent in Kaposis Sarcoma
Jul 02, 2015: Macrophage Therapeutics Reports Data Demonstrating a Manocept Drug Conjugate Induces Apoptosis in CD206 Positive Kaposis Sarcoma and Tumor Associated Macrophages
Jun 29, 2015: CytRx Announces Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposi's Sarcoma
Jan 20, 2015: CytRx Announces FDA's Removal of Partial Clinical Hold for Aldoxorubicin Clinical Trials Permitting Immediate Enrollment of New Patients
Jan 08, 2015: CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results as a Treatment for HIV-Related Kaposi's Sarcoma
Jan 23, 2014: CytRx Initiates Phase 2 Clinical Trial with Aldoxorubicin for First-Line Treatment of AIDS-Related Kaposis Sarcoma
Apr 26, 2013: Cannabis Science Announces Preclinical Development Program For CS-TATI-I
Nov 12, 2012: Beth Israel Deaconess Medical Center, Harvard Medical School Study Confirms Cannabis Science's Approach To Development Of CS-TATI-1 To Inhibit Kaposi Sarcoma
Sep 24, 2012: Cannabis Science Initiates Preclinical Investigation Of CS-TATI-1 For European Studies For Squamous/Basal Cell Carcinomas And Kaposis Sarcoma
Aug 13, 2012: CBIS Initiates GMP Development Plan For CS-TATI-1
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Kaposi Sarcoma, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Kaposi Sarcoma - Pipeline by Aphios Corp, H1 2017
Kaposi Sarcoma - Pipeline by Cannabis Science Inc, H1 2017
Kaposi Sarcoma - Pipeline by CytRx Corp, H1 2017
Kaposi Sarcoma - Pipeline by LATITUDE Pharmaceuticals Inc, H1 2017
Kaposi Sarcoma - Pipeline by RedHill Biopharma Ltd, H1 2017
Kaposi Sarcoma - Pipeline by Tumorend LLC, H1 2017
Kaposi Sarcoma - Pipeline by VasGene Therapeutics Inc, H1 2017
Kaposi Sarcoma - Dormant Projects, H1 2017
Kaposi Sarcoma - Dormant Projects, H1 2017 (Contd..1), H1 2017
Kaposi Sarcoma - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Kaposi Sarcoma, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *